Chronic graft versus host disease pharmacology

Thomas Hughes, Timothy R McGuire

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter focuses on the pharmacology, pharmacokinetics, drug interactions, and toxicity of commonly utilized immunosuppressive agents in the management of chronic graft versus host disease (cGVHD). The agents selected for review within this chapter include the corticosteroids, the calcineurin inhibitors, mycophenolate mofetil, thalidomide, and sirolimus. Table 10.1 summarizes additional pharmacologic agents that have been utilized for the systemic management of cGVHD. CORTICOSTEROIDS. Corticosteroids and, most notably, prednisone are generally considered the mainstay and drug of choice for the initial treatment of cGVHD. Prednisone has utility as a single agent in the initial therapy of cGVHD, particularly in standard risk patients and in combination therapy with a calcineurin inhibitor, such as cyclosporine, for high-risk patients. The clinical application of prednisone in the treatment of cGVHD is summarized in Chapter 12. Pharmacology. Corticosteroids impact an extensive number of physiologic functions within the body including carbohydrate, protein, and lipid metabolism; maintenance of fluid and electrolyte balance; and preservation of a variety of organ systems including the cardiovascular, immune, skeletal muscle, renal, endocrine, and nervous systems. Corticosteroids are classified according to their relative potencies in sodium retention (i.e., mineralocorticoid activity) and their effects on glucose or carbohydrate metabolism (i.e., glucocorticoid activity). The potency of a corticosteroid to impact glucose metabolism closely parallels those for anti-inflammatory activity (refer to Table 10.2).

Original languageEnglish (US)
Title of host publicationChronic Graft Versus Host Disease: Interdisciplinary Management
PublisherCambridge University Press
Pages101-116
Number of pages16
ISBN (Print)9780511576751, 9780521884235
DOIs
StatePublished - Jan 1 2009

Fingerprint

Graft vs Host Disease
Adrenal Cortex Hormones
Pharmacology
Prednisone
Water-Electrolyte Balance
Carbohydrate Metabolism
Mycophenolic Acid
Glucose
Mineralocorticoids
Endocrine System
Thalidomide
Sirolimus
Therapeutics
Immunosuppressive Agents
Cardiovascular System
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Lipid Metabolism
Nervous System
Cyclosporine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hughes, T., & McGuire, T. R. (2009). Chronic graft versus host disease pharmacology. In Chronic Graft Versus Host Disease: Interdisciplinary Management (pp. 101-116). Cambridge University Press. https://doi.org/10.1017/CBO9780511576751.011

Chronic graft versus host disease pharmacology. / Hughes, Thomas; McGuire, Timothy R.

Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge University Press, 2009. p. 101-116.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hughes, T & McGuire, TR 2009, Chronic graft versus host disease pharmacology. in Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge University Press, pp. 101-116. https://doi.org/10.1017/CBO9780511576751.011
Hughes T, McGuire TR. Chronic graft versus host disease pharmacology. In Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge University Press. 2009. p. 101-116 https://doi.org/10.1017/CBO9780511576751.011
Hughes, Thomas ; McGuire, Timothy R. / Chronic graft versus host disease pharmacology. Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge University Press, 2009. pp. 101-116
@inbook{7ab24309ca5343a0b0235b6d232158c3,
title = "Chronic graft versus host disease pharmacology",
abstract = "This chapter focuses on the pharmacology, pharmacokinetics, drug interactions, and toxicity of commonly utilized immunosuppressive agents in the management of chronic graft versus host disease (cGVHD). The agents selected for review within this chapter include the corticosteroids, the calcineurin inhibitors, mycophenolate mofetil, thalidomide, and sirolimus. Table 10.1 summarizes additional pharmacologic agents that have been utilized for the systemic management of cGVHD. CORTICOSTEROIDS. Corticosteroids and, most notably, prednisone are generally considered the mainstay and drug of choice for the initial treatment of cGVHD. Prednisone has utility as a single agent in the initial therapy of cGVHD, particularly in standard risk patients and in combination therapy with a calcineurin inhibitor, such as cyclosporine, for high-risk patients. The clinical application of prednisone in the treatment of cGVHD is summarized in Chapter 12. Pharmacology. Corticosteroids impact an extensive number of physiologic functions within the body including carbohydrate, protein, and lipid metabolism; maintenance of fluid and electrolyte balance; and preservation of a variety of organ systems including the cardiovascular, immune, skeletal muscle, renal, endocrine, and nervous systems. Corticosteroids are classified according to their relative potencies in sodium retention (i.e., mineralocorticoid activity) and their effects on glucose or carbohydrate metabolism (i.e., glucocorticoid activity). The potency of a corticosteroid to impact glucose metabolism closely parallels those for anti-inflammatory activity (refer to Table 10.2).",
author = "Thomas Hughes and McGuire, {Timothy R}",
year = "2009",
month = "1",
day = "1",
doi = "10.1017/CBO9780511576751.011",
language = "English (US)",
isbn = "9780511576751",
pages = "101--116",
booktitle = "Chronic Graft Versus Host Disease: Interdisciplinary Management",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Chronic graft versus host disease pharmacology

AU - Hughes, Thomas

AU - McGuire, Timothy R

PY - 2009/1/1

Y1 - 2009/1/1

N2 - This chapter focuses on the pharmacology, pharmacokinetics, drug interactions, and toxicity of commonly utilized immunosuppressive agents in the management of chronic graft versus host disease (cGVHD). The agents selected for review within this chapter include the corticosteroids, the calcineurin inhibitors, mycophenolate mofetil, thalidomide, and sirolimus. Table 10.1 summarizes additional pharmacologic agents that have been utilized for the systemic management of cGVHD. CORTICOSTEROIDS. Corticosteroids and, most notably, prednisone are generally considered the mainstay and drug of choice for the initial treatment of cGVHD. Prednisone has utility as a single agent in the initial therapy of cGVHD, particularly in standard risk patients and in combination therapy with a calcineurin inhibitor, such as cyclosporine, for high-risk patients. The clinical application of prednisone in the treatment of cGVHD is summarized in Chapter 12. Pharmacology. Corticosteroids impact an extensive number of physiologic functions within the body including carbohydrate, protein, and lipid metabolism; maintenance of fluid and electrolyte balance; and preservation of a variety of organ systems including the cardiovascular, immune, skeletal muscle, renal, endocrine, and nervous systems. Corticosteroids are classified according to their relative potencies in sodium retention (i.e., mineralocorticoid activity) and their effects on glucose or carbohydrate metabolism (i.e., glucocorticoid activity). The potency of a corticosteroid to impact glucose metabolism closely parallels those for anti-inflammatory activity (refer to Table 10.2).

AB - This chapter focuses on the pharmacology, pharmacokinetics, drug interactions, and toxicity of commonly utilized immunosuppressive agents in the management of chronic graft versus host disease (cGVHD). The agents selected for review within this chapter include the corticosteroids, the calcineurin inhibitors, mycophenolate mofetil, thalidomide, and sirolimus. Table 10.1 summarizes additional pharmacologic agents that have been utilized for the systemic management of cGVHD. CORTICOSTEROIDS. Corticosteroids and, most notably, prednisone are generally considered the mainstay and drug of choice for the initial treatment of cGVHD. Prednisone has utility as a single agent in the initial therapy of cGVHD, particularly in standard risk patients and in combination therapy with a calcineurin inhibitor, such as cyclosporine, for high-risk patients. The clinical application of prednisone in the treatment of cGVHD is summarized in Chapter 12. Pharmacology. Corticosteroids impact an extensive number of physiologic functions within the body including carbohydrate, protein, and lipid metabolism; maintenance of fluid and electrolyte balance; and preservation of a variety of organ systems including the cardiovascular, immune, skeletal muscle, renal, endocrine, and nervous systems. Corticosteroids are classified according to their relative potencies in sodium retention (i.e., mineralocorticoid activity) and their effects on glucose or carbohydrate metabolism (i.e., glucocorticoid activity). The potency of a corticosteroid to impact glucose metabolism closely parallels those for anti-inflammatory activity (refer to Table 10.2).

UR - http://www.scopus.com/inward/record.url?scp=84928926233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928926233&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511576751.011

DO - 10.1017/CBO9780511576751.011

M3 - Chapter

SN - 9780511576751

SN - 9780521884235

SP - 101

EP - 116

BT - Chronic Graft Versus Host Disease: Interdisciplinary Management

PB - Cambridge University Press

ER -